Susan Lynch, NP
Nurse Practitioner · Chattanooga, TNNPI 1760462303
Payments from drug & device makers
Across 120 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$400
- AbbVie$282
- Pfizer$260
- Boston Scientific$249
- Lilly USA, LLC$164
- Biohaven Pharmaceuticals, Inc.$145
- plus $781 from 21 others
What the payments were for
- Food & beverage$2,18796%
- Education$944%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $400 |
| AbbVie | 17 | $282 |
| Pfizer | 15 | $260 |
| Boston Scientific | 9 | $249 |
| Lilly USA, LLC | 10 | $164 |
| Biohaven Pharmaceuticals, Inc. | 3 | $145 |
| GSK | 9 | $139 |
| Astellas Pharma US Inc | 2 | $110 |
| Bayer | 5 | $92 |
| AstraZeneca | 5 | $69 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Abbott | 2 | $40 |
| Amgen | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Endotronix, Inc. | 1 | $21 |
| Nevro Corp. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Intra-sana Laboratories | 1 | $14 |
| Upsher-smith Laboratories LLC | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
How this compares
$2,281 in reported general payments places this provider in the 80th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $86,613 |
| FarxigaDapagliflozin Propanediol | 60 | $71,424 |
| EliquisApixaban | 66 | $65,776 |
| MounjaroTirzepatide | 21 | $47,755 |
| TrulicityDulaglutide | 24 | $30,888 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $26,921 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $20,172 |
| CreonLipase/Protease/Amylase | 14 | $15,442 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $14,533 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $14,468 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $7,180 |
| Atorvastatin Calcium | 393 | $6,000 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,251 |
| Rosuvastatin Calcium | 327 | $4,268 |
| Potassium Chloride | 140 | $3,964 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $400 | $86,61367 claims |
| Lilly USA, LLCMounjaro, Trulicity | $164 | $78,64345 claims |
| AstraZenecaFarxiga | $69 | $71,42460 claims |
| PfizerEliquis, Paxlovid | $260 | $67,09481 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $139 | $41,38950 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $41 | $20,17212 claims |
| AbbVieCreon, Synthroid | $282 | $17,94757 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Chattanooga
- Cynthia WilsonChattanooga$62K
- Honor HightshueChattanooga$45K
- Amy OttmanChattanooga$32K
- Philip AndrewsChattanooga$18K
- Amberly EllisChattanooga$17K
- Erin StockwellChattanooga$15K
- Teresa DeeseChattanooga$13K
- Jay PassmoreChattanooga$13K
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.